Cyclosporine: effective treatment for patients with inflammation of the ocular surface Review article
Article Sidebar
Main Article Content
Abstract
Dry eye syndrome is a multifactorial and multisymptomatic disease affecting millions of people worldwide. Statistics show that depending on geographic location, 15% to 30% of a country’s population suffers from dry eye syndrome. Chronic inflammation leads to structural changes on the surface of the eye, causing pain and a range of other distressing symptoms. If left untreated, these symptoms can eventually result in reduced visual acuity and difficulties performing typical daily activities. The decline in quality of life strongly correlates with a deterioration in mental health. Recent studies indicate that one in three dry eye syndrome patients may struggle with depression. Chronic dry eye syndrome triggers the development of neurogenic inflammation. The aim of this study is to present the indications for and mechanism of action of cyclosporine A in the treatment of this condition.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Toker E, Asfuroğlu E. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Cornea. 2010; 29: 133-40.
3. Pisella PJ, Labetoulle M, Doan S et al. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. Clin Ophthalmol. 2018; 12: 289-99.
4. Straub M, Bron A, Muselier-Mathieu A et al. Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up. Br J Ophthalmol. 2016; 100(11): 1547-50.
5. Opala A, Wiącek D, Grabska-Liberek I. Zespół suchego oka – jak diagnozować i kiedy leczyć w gabinecie lekarza POZ. Lekarz POZ. 2022; 8(1): 78-81.
6. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995; 21: 221-32.
7. Lemp MA. Management of dry eye disease. Am J Manag Care. 2008; 14(3 Suppl): S88-101.
8. Toyos R, Desai NR, Toyos M et al. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. PLoS One. 2022; 17(6): e0270268.
9. Moon SY, Chung HS, Lee JH et al. Effectiveness of cyclosporine nanoemulsion eye drops in patients with mild-to-moderate dry eyes: objective and subjective evaluation. BMC Ophthalmol. 2024; 24(1): 401.
10. Schultz C. Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye. Ophthalmol Eye Dis. 2014; 6: 37-42.
11. Haddad EM, McAlister VC, Renouf E et al. Cyclosporin versus tacrolimus for liver transplanted patients Cochrane Database Syst Rev. 2006; 4: CD005161.
12. Pieczyński J, Kuklo P. Cyclosporine A in treatment of dry eye disease. Ophthatherapy 2018; 5(2): 85-9.
13. Wytyczne PTO, PTR, PTHiT dot. zapobiegania i leczenia ciężkiego zapalenia rogówki w przebiegu ZSO.
14. Levy O, Labbé A, Borderie V et al. [Topical cyclosporine in ophthalmology: Pharmacology and clinical indications]. Ophtalmol. 2016; 39(3): 292-307.
15. Mandal N, Yeung SN, Tadrous C et al. Thygeson’s superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol. 2022; 260(6): 1837-41.
16. Zhang Q, Bao N, Liang K et al. Adjuvant Use of Cyclosporine A in the Treatment of Primary Pterygium: A Systematic Review and Meta-Analysis. Cornea. 2018; 37(8): 1000-7.
17. Leonardi A, Flamion B, Baudouin C. Keratitis in Dry Eye Disease and Topical Ciclosporin A. Ocul Immunol Inflamm. 2017; 25(4): 577-86.
18. Służba Zdrowia. Ikervis.